Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Orthocell Ltd ( (AU:OCC) ) has provided an update.
Orthocell Limited has successfully raised $30 million through an institutional placement, attracting significant interest from US and international investors. The funds will be used to accelerate the US rollout of Remplir, expand manufacturing capacity, and advance clinical studies for its use in prostate cancer surgeries. The company is also investing in new regenerative medicine applications, positioning itself strongly in the global market with over $50 million in cash and no debt. This strategic financial move is expected to enhance Orthocell’s market position and drive growth, particularly in the US, where the company has already achieved significant milestones in its commercial operations.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company focused on developing and commercializing innovative medical products. Its primary product, Remplir, is a flagship nerve repair product, and the company is also advancing products in tendon, ligament, and bone repair. Orthocell is actively expanding its market presence, particularly in the United States.
Average Trading Volume: 604,813
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$354.4M
For an in-depth examination of OCC stock, go to TipRanks’ Overview page.